<DOC>
	<DOCNO>NCT00563108</DOCNO>
	<brief_summary>Graft-versus-host disease ( GVHD ) contribute substantially transplant-related morbidity mortality . Steroids remain first line therapy acute GVHD currently consensus second line therapy steroid ineffective . Basiliximab show safe effective immunosuppresant prevention treatment rejection renal transplantation role acute GVHD prophylaxis treatment describe favourably . This randomize control trial investigate efficacy safety management acute GVHD post allogeneic stem cell transplantation ( SCT ) .</brief_summary>
	<brief_title>Basiliximab Treatment Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Grade II IV acute GVHD SCT Known allergy basilixmab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Acute graft-versus-host disease post allogeneic stem cell transplantation</keyword>
</DOC>